Korean J Ophthalmol.  2006 Sep;20(3):166-170. 10.3341/kjo.2006.20.3.166.

Ocular Hypertensive Response to Topical Dexamethasone Ointment in Children

• Lee YJ
• Park CY
• Woo KI

• KMID: 754574
• DOI: http://doi.org/10.3341/kjo.2006.20.3.166

Abstract

PURPOSE: To investigate the rate and the degree of the ocular hypertensive response to dexamethasone ointment in children undergoing eyelid surgery. METHODS: Dexamethasone ointment (Dexcosil(R)) was applied three times a day for the first week and twice a day for the second to third week postoperatively to children undergoing epiblepharon surgery. Intraocular pressure (IOP) was measured on the day before surgery, postoperative day 1, 7, 14, 21, 28 and 2 weeks thereafter until the IOP reached preoperative levels. Peak IOP, IOP net increase and time to reach a peak IOP were analyzed. Dexamethasone ointment was discontinued if the IOP was 25 mmHg or more. RESULTS: A total of 96 children (mean age, 6.5+/-2.7 years) were included. Preoperative mean IOP was 13.6+/-2.9 mmHg (range 7-19). After dexamethasone ointment treatment, the children showed a significant rise in IOP as compared with the preoperative values. The peak IOP was 20.6+/-4.9 mmHg (range 11-39) and the time to reach peak IOP was 8.5+/-5.9 days. The low responders (delta IOP< or =5 mmHg) of our group comprised 35.4% (34/96) of patients, intermediate responders (delta IOP 6-15 mmHg) comprised 56.3% (54/96) of patients and high responders (delta IOP> or =16) comprised 8.3% (8/96) of patients. A net increase in IOP was significantly higher in children 5 years old or less as compared with those older than 5 years (age< or =5, 9.4+/-7.5 mmHg vs age>5, 6.3+/-4.4 mmHg; p=0.015, unpaired t-test). CONCLUSIONS: Ocular hypertensive response after dexamethasone ointment to the eyelids occurred frequently in children, especially those 5 years old or younger.

Keyword

Children; Dexamethasone; Epiblepharon; Intraocular pressure

MeSH Terms

Prospective Studies
Prognosis
Postoperative Period
Ointments
Ocular Hypertension/*chemically induced/physiopathology
Male
Intraocular Pressure/*drug effects
Humans
Glucocorticoids/administration & dosage/*adverse effects
Follow-Up Studies
Female
Eyelid Diseases/surgery
Dexamethasone/administration & dosage/*adverse effects
Child, Preschool
Child
Adult
Adolescent
Administration, Topical

Reference

1. Woo KI, Yi KY, Kim YD. Surgical correction for lower lid epiblepharon in Asians. Br J Ophthalmol. 2000. 84:1407–1410.

2. Baraz KH, Hattenhauer MG. Indiscriminative use of corticosteroid-containing eyedrops. Mayo Clinic proceeding. 1999. 74:362–366.

3. Vajpayee RB, Gupta SK, Bareja U, Kishore K. Ocular atopy and mycotic keratitis. Ann Ophthalmol. 1990. 22:369–372.

4. Kaufmann HE. Use of corticosteroids in corneal disease and external disease of the eye. Int Ophthalmol Clin. 1966. 6:827–843.

5. Allingham RR, Damji KF, Freedman S, et al. Shields' Textbook of Glaucoma. 2005. 5th ed. Philadelpia: Lippincott Williams & Wilkins;387–392.

6. Sahni D, Darley CR, Hawk JLM. Glaucoma induced by periorbital topical steroid use-a rare complication. Clin Exp Dermatol. 2004. 29:617–619.

7. Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol. 1965. 4:198–205.

8. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics. II. The effect of dexamethasone in the glaucomatous eye. Arch Ophthalmol. 1963. 70:492–499.

9. Myers KJ, Lakke P, Litwak A, et al. XPERT NCT-a clinical evaluation. J Am Optom Assoc. 1990. 61:63–69.

10. Eisenberg DL, Sherman BG, Mckeown CA, Schuman JS. Tonometry in adults and children. A manometric evaluation of peumatonometry, applanation, and TonoPen in vitro and in vivo. Ophthalmology. 1998. 105:1173–1181.

11. Armaly MF. Statistical attributes of steroid hypertensive response in the clinically normal eye. Invest-Ophthahalmol. 1965. 4:187–189.

12. Kaye LD, Kalenak JW, Price RL, et al. Ocular implications of long tern prednisone therapy in children. J Pediatr Ophththalmol Strabismus. 1993. 30:142–147.

13. Biender BZ, David R, Grudsky A, et al. Intraocular pressure response to corticosteroids in children. Br J Ophthalmol. 1980. 64:430–431.

14. Ohji M, Kinoshita S, Ohmi E, et al. Marked intraocular pressure to instillation of corticosteroids in children. Am J Ophthalmol. 1991. 112:450–454.

15. Kwok AK, Lam DS, Ng JS, et al. Ocular hypertensive response to topical steroids in children. Ophthalmology. 1997. 104:2112–2116.

16. Lam DS, Fan DS, Ng JS, et al. Ocular hypertensive response and anti-inflammatory response to different dosage of topical dexamethasone in children: a randomized trial. Clin & Exp Ophthalmol. 2005. 33:252–258.

17. Ng JS, Fan DS, Young AL, et al. Ocular hypertensive response to topical dexamethasone in children: a dose-dependent phenomenon. Ophthalmology. 2000. 107:2097–2100.

18. Cubey RB. Glaucoma following the application of corticosteroid to the skin of the eyelids. BR J Dermatol. 1976. 95:207–208.

19. Chua JK, Fan DS, Leung AT, et al. Accelerated ocular hypertension after application of corticosteroid ointment to a child's eyelid. Mayo Clin Proc. 2005. 75:539–542.

20. Knepper PA, Collins JA, Frederick R. Effect of dexamethasone, progesterone, and testosterone on IOP and GAGs in the rabbit eye. Invest Ophthalmol Vis Sci. 1985. 26:1093–1099.

21. Clark AF, Wilson K, de Kater AW, et al. Dexamethasone induced ocular hypertension in perfusion-cultured human eyes. Invest Ophthalmol Vis Sci. 1995. 36:478–479.

22. Hernandez MR, Weinstein BI, Dunn MW, et al. The effect of dexamethasone on the synthesis of collagen in normal human trabecular meshwork explants. Invest Ophthalmol Vis Sci. 1985. 26:1784–1789.

23. Reme C, Depinay SL. Periods of development of the normal human chamber angle. Doc Ophthalmol. 1981. 51:241–268.

24. Knepper PA, Breen M, Weistein HG, Blacik JL. Intraocular pressure and glycosaminoglycan distribution in the rabbit eye: effect of age and dexamethasone. Exp Eye Res. 1978. 27:567–575.

25. Weinreb RN, Polansky JR, Kramer SG, Baxter JD. Acute effects of dexamethasone on intraocular pressure in glaucoma. Invest Ophthalmol Vis Sci. 1985. 26:170–175.